Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Minerva Neurosciences, Inc. (NERV) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 8-K Quarterly results
05/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/01/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia"
12/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Investor inquiries: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. [email protected] Media inquiries:"
12/16/2022 8-K Quarterly results
12/02/2022 8-K Quarterly results
10/17/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Investor inquiries: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. [email protected] Media inquiries:"
09/09/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market BURLINGTON, Mass. - September 9, 2022 - Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported a listing transfer from The Nasdaq Global Market to The Nasdaq Capital Market. The Company announced today that it received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market that the Company's application to transfer its common stock from The Nasdaq Global Market to The Nasdaq Capital Market, as allowed under Listing Rule 5810, had been approved. The Company's common stock will begin trading on The Nasdaq Capital Market effective at the start of trading on September 12, 2022. T..."
08/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor inquiries: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. [email protected] Media inquiries:"
06/17/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
04/13/2022 8-K Investor presentation
Docs: "Presentation of Minerva Neurosciences, Inc.",
"Presentation of Minerva Neurosciences, Inc."
04/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Inquiries: Frederick Ahlholm Chief Financial Officer Minerva Neurosciences, Inc. [email protected] Media inquiries:"
03/14/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
02/28/2022 8-K Quarterly results
01/18/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
01/05/2022 8-K Investor presentation
Docs: "Presentation of Minerva Neurosciences, Inc.",
"Presentation of Minerva Neurosciences, Inc."
12/08/2021 8-K Quarterly results
11/03/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission Waltham, Mass. - November 3, 2021 - Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that the U. S. Food and Drug Administration has denied the company's request for a pre-NDA meeting for roluperidone and responded that a Type C guidance meeting would be more appropriate to discuss the evidence for use of roluperidone as monotherapy. Subject to the timing of and feedback from the FDA at a Type C guidance meeting, which the Company plan..."
10/12/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "First Amendment to the Employment Agreement of Geoff Race by and between Mind-NRG SARL and Geoff Race, effective October 11, 2021",
"Amended and Restated Employment Agreement by and between Minerva Neurosciences, Inc. and Frederick Ahlholm, effective October 11, 2021",
"Minerva Neurosciences Announces Promotion of Geoff Race to President"
09/30/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia"
09/08/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Transition, Separation, and Consulting Agreement by and between Minerva Neurosciences, Inc. and Jay B. Saoud",
"MINERVA NEUROSCIENCES ANNOUNCES APPOINTMENT OF DR. RAMANA KUCHIBHATLA AS SENIOR VICE PRESIDENT AND HEAD OF RESEARCH & DEVELOPMENT Dr. Jay Saoud, Head of Research & Development, to retire from his current role and transition to an advisory role in which he will continue to support the preparation and planned submission of a New Drug Application for Minerva's lead program, roluperidone Waltham, MA, September 8, 2021 - Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced Dr. Jay Saoud's retirement and transition to an advisory role and Dr. Ramana Kuchibhatla's appointment as Senior Vice President and Head of Research & Development, both effective September 16, 2021. Dr. Kuchi..."
06/16/2021 8-K Quarterly results
04/19/2021 8-K Quarterly results
01/19/2021 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "MINERVA NEUROSCIENCES AND ROYALTY PHARMA ANNOUNCE SALE OF SELTOREXANT ROYALTY FOR UP TO $155 MILLION"
12/01/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone"
10/14/2020 8-K Quarterly results
09/08/2020 8-K Quarterly results
07/02/2020 8-K Quarterly results
07/01/2020 8-K Quarterly results
06/25/2020 8-K Quarterly results
06/05/2020 8-K Investor presentation
Docs: "Corporate Presentation"
05/29/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 29, 2020 Minerva Neurosciences, Inc. Delaware 001-36517 26-0784194 1601 Trapelo Road Suite 286 Waltham, MA 02451 : 600-7373 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under the Excha...",
"MINERVA NEUROSCIENCES ANNOUNCES RESULTS FROM PHASE 3 TRIAL OF ROLUPERIDONE FOR TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA • The 64 mg and 32 mg doses were not statistically significantly different from placebo at Week 12 on the primary endpoint, the PANSS Marder Negative Symptoms Factor Score , or the key secondary endpoint, the Personal and Social Performance Scale Total Score • Roluperidone separated from placebo on both primary and key secondary endpoints at Weeks 4, 8 and 12 • Roluperidone was generally well tolerated with a safety profile comparable to placebo Waltham, MA, May 29, 2020 - Minerva Neurosciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the Phase 3 trial ..."
04/01/2020 8-K Investor presentation
Docs: "Company Presentation",
"Company Presentation"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy